A Phase 1, Open Label, Single-period, Non-randomized Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance, And Metabolism Of [14c]Pf-05221304 Administered Orally To Healthy Adult Male Subjects
Phase of Trial: Phase I
Latest Information Update: 07 Oct 2018
Price : $35 *
At a glance
- Drugs PF 5221304 (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 12 Jun 2018 Status changed from recruiting to completed.
- 11 May 2018 Planned End Date changed from 1 Jun 2018 to 13 Jun 2018.
- 11 May 2018 Planned primary completion date changed from 1 May 2018 to 20 May 2018.